In This Section

Program

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

Thursday, October 5

Welcome and Opening Keynote

Friday, October 6

Plenary Session 1: Tumor Microenvironment and Immune Oncology I
Proffered Talks I
Plenary Session 2: Rare Ovarian Tumors
Plenary Session 3: Drug Discovery, Development, and Novel Pathways
Plenary Session 4: Early Detection and Prevention

Saturday, October 7

Plenary Session 5: Epigenetics and Epitranscriptomics
Keynote Lecture II
Proffered Talks II
Plenary Session 6: Tumor Microenvironment and Immune Oncology II

Thursday, October 5

Welcome and Opening Keynote
5-6 P.M.

Welcome from Conference Cochairs

Opening Keynote
David D.L. Bowtell, Peter MacCallum Cancer Center, Victoria, Australia

Break
6-6:30 P.M.
Poster Session A/Opening Reception
6:30-8 P.M.

Friday, October 6

Continental Breakfast
7-8 A.M.
Plenary Session 1: Tumor Microenvironment and Immune Oncology I
8-10 A.M.

Fallopian tube precursors make tumors nervous
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, Pennsylvania

Regional combating of immunosuppressive forces in the ovarian tumor microenvironment
Daniel J. Powell Jr., University of Pennsylvania, Philadelphia, PA

Friend or foe: Reevaluating the therapeutic potential of monocytes and tumor-associated macrophages in ovarian cancer                                                                                            Oladapo O. Yeku, Massachusetts General Hospital, Boston, MA

Two short talks selected from proffered abstracts

Break
10-10:15 A.M.
Proffered Talks I
10:15-11:15 A.M.
Lunch (On Own)
11:45 A.M.-12:45 P.M.
Plenary Session 2: Rare ovarian tumors
12:45-2:15 P.M.

Tumor heterogeneity of ovarian clear cell carcinoma
Ruby Yun-Ju Huang, National Taiwan University, Teipei, Taiwan

Title to be announced
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

Epigenetic approaches for endometriosis-associated ovarian cancer
Rugang Zhang, MD Anderson Cancer Center, Houston, Texas

Break
2:15-2:30 P.M.
Plenary Session 3: Drug Discovery, Development, and Novel Pathways
2:30-4:30 P.M.

Latest developments in targeting the DNA damage response in the clinic
Timothy A. Yap, MD Anderson Cancer Center, Houston, Texas

Advancing novel therapeutics through reverse translation
Sarah F. Adams, University of New Mexico, Albuquerque, New Mexico

Targeting AXL in platinum-resistant ovarian cancer: From the lab bench to Phase 3 trial
Katherine C. Fuh, University of California San Francisco, San Francisco, California

Cell cycle checkpoint pathways as therapeutic target
Jung-min Lee, National Cancer Institute, Bethesda, Maryland

Break
4:30-5 P.M.
PLENARY SESSION 4: Early Detection and Prevention
5-7 P.M.

Improving targeted precision prevention in ovarian cancer
Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London, London, England

Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let’s prove it!
Kathryn P. Pennington, University of Washington, Seattle, Washington

Opportunistic salpingectomy for ovarian cancer prevention
Gillian Hanley, University of British Columbia, Vancouver, BC, Canada

AI-enabled liquid biopsy for ovarian cancer detection
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Session B/Reception
7-8:30 P.M.

Saturday, October 7

Continental Breakfast
7-8 A.M.
Plenary Session 5: Epigenetics and Epitranscriptomics
8-10 A.M.

FTO-regulated m6A modifications in ovarian cancer
Daniela E. Mattei, Northwestern University, Chicago, Illinois

Title to be announced
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, California

Targeting transposable elements with epigenetic modulators to reverse ovarian cancer immune evasion
Katherine B. Chiappanelli, The George Washington University School of Medicine and Health Sciences, Washington D.C.

Two short talks selected from proffered abstracts

Break
10-10:30 A.M.
Keynote Lecture II
10:30-11:15 A.M.

Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, Michigan

Proffered Talks II
11:15 A.M.-12:15 P.M.
Extended Break
12:15-1:00 P.M.
Plenary Session 6: Tumor Microenvironment and Immune Oncology II
12:45-2:15 P.M.

B cells: the immune system’s secret weapon against ovarian cancer
Brad Nelson, University of British Columbia, Vancouver, BC, Canada

Spatial multiomics allows identifying the genomic and proteomic changes from borderline to low-grade serous cancer
Ernst R. Lengyel, University of Chicago, Chicago, Illinois

Mutational processes as determinants of immune evasion in ovarian cancer
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Two short talks selected from proffered abstracts

Closing Remarks
2:15 P.M.